Defence Therapeutics Inc.

Montreal, QC, Canada, February 4th, 2026 – Defence Therapeutics Inc. (“Defence” or the “Company”), a publicly traded biotechnology and precision intracellular drug-delivery company, today announced that it will present at World ADC Europe 2026, taking place February 23–26, 2026, in London, UK.  Defence will showcase its proprietary Accum® platform, a...

Montreal, QC, Canada, January 28th, 2026 - Defence Therapeutics Inc. (“Defence” or the “Company”), a publicly traded biotechnology and precision intracellular drug-delivery company, today announced the strengthening of its long-standing collaboration with Canadian Nuclear Laboratories (“CNL”) as part of its strategic effort to accelerate and expand its proprietary radiopharmaceutical program. Defence...

Montreal, QC, Canada, January 21st, 2026 - Defence Therapeutics Inc., (“Defence” or the “Company”), a publicly traded biotechnology company, today announced an evolution of its corporate positioning to reflect its focus as a precision intracellular drug-delivery company advancing its proprietary Accum® platform through both internal development programs and strategic partnerships....

Montreal, QC, Canada, December 4th, 2025 - Defence Therapeutics Inc. (“Defence” or the “Company”), a biotechnology company advancing a proprietary intracellular delivery platform that enables more potent, safer, and more effective antibody-based and radiotherapeutic treatments, is pleased to announce the formation of its inaugural Scientific Advisory Board (“SAB”), composed of...

Montreal, QC, Canada, December 4th, 2025 - Defence Therapeutics Inc. (“Defence” or the “Company”), a biotechnology company advancing a proprietary intracellular delivery platform that enables more potent, safer, and more effective antibody-based and radiotherapeutic treatments, is pleased to announce the formation of its inaugural Scientific Advisory Board (“SAB”), composed of...

Montreal, QC, Canada, November 19th, 2025 - Defence Therapeutics Inc. (“Defence” or the “Company”), a leading biotechnology company pioneering next-generation antibody-drug conjugate (“ADC”), is pleased to announce a major step forward in the fight against cancer that goes beyond the ADCs current limitations.  Following successful presentations and meetings at the...